← Back to Search

Screening Program for Multiple Myeloma

N/A

Recruiting

Led By Jason Valent, MD

Research Sponsored by Case Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50 years of age or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial seeks to develop a program to better understand and detect multiple myeloma early, including analyzing community understanding and participation in screening, and providing patient navigation for those with abnormal results. #MM #Screening

Who is the study for?

This trial is for Black and/or African-American individuals who are 50 years or older. It aims to promote early detection of multiple myeloma by screening participants and providing guidance if abnormal results are found.Check my eligibility

What is being tested?

The study tests a community outreach program that includes MM screening using M-Protein analysis, followed by patient navigation for those with abnormal results. It also assesses participant knowledge about MM through questionnaires.See study design

What are the potential side effects?

Since this trial involves screening and questionnaires rather than medical treatments, there are no direct side effects associated with the interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To conduct and evaluate a study that incorporates patient navigation programs to recruit and screen participants for Multiple Myeloma and its disease precursors, MGUS or smoldering MM

To study participant knowledge of Multiple Myeloma

Trial Design

1Treatment groups

Experimental Treatment

Group I: Multiple Myeloma Screening ExperienceExperimental Treatment2 Interventions

Participants will partake in a multiple myeloma screening program. The screening involves a blood sample and the completion of a questionnaire to gauge participants' multiple myeloma knowledge.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor

453 Previous Clinical Trials

31,690 Total Patients Enrolled

26 Trials studying Multiple Myeloma

1,505 Patients Enrolled for Multiple Myeloma

Jason Valent, MDPrincipal InvestigatorCleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

1 Previous Clinical Trials

16 Total Patients Enrolled

1 Trials studying Multiple Myeloma

16 Patients Enrolled for Multiple Myeloma

Media Library

Multiple Myeloma M-Protein Analysis Clinical Trial Eligibility Overview. Trial Name: NCT05831358 — N/A

Multiple Myeloma Research Study Groups: Multiple Myeloma Screening Experience

Multiple Myeloma Clinical Trial 2023: Multiple Myeloma M-Protein Analysis Highlights & Side Effects. Trial Name: NCT05831358 — N/A

Multiple Myeloma M-Protein Analysis 2023 Treatment Timeline for Medical Study. Trial Name: NCT05831358 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for participants in this research project?

"Unfortunately, appropriate participants for this clinical trial are no longer being sought out. The protocol was initially posted on May 1st 2023 and the last update to its details occurred April 14th of that same year. Fortunately, there remain 815 other studies actively recruiting patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

2023. "Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05831358.